Atrium Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-58.69	-49.5	-25.12	-6.39
Depreciation & Amortization	0.42	0.32	0.17	0.14
Loss (Gain) From Sale of Assets	0.14	0.14	-	-
Stock-Based Compensation	18.68	7.68	3.18	2.51
Other Operating Activities	1.22	0.43	12.11	0.2
Change in Accounts Receivable	-15	-	0.75	1.39
Change in Accounts Payable	0.1	3.73	0.03	-0.05
Change in Unearned Revenue	-11.68	-8.62	-10.11	62.78
Change in Other Net Operating Assets	3.64	4.69	-3.56	-4.19
Operating Cash Flow	-61.17	-41.13	-22.55	56.39
Capital Expenditures	-3.54	-1.45	-0.27	-0.32
Investing Cash Flow	-3.54	-1.45	-0.27	-0.32
Other Financing Activities	332.98	42.57	22.82	-56.07
Financing Cash Flow	332.98	42.57	22.82	-56.07
Free Cash Flow	-64.71	-42.57	-22.82	56.07
Free Cash Flow Margin	-176.42%	-228.67%	-209.41%	574.25%
Free Cash Flow Per Share	-3.78	-2.74	-	-
Levered Free Cash Flow	-	-11.65	-12.01	-
Unlevered Free Cash Flow	-	-11.65	-12.01	-
Change in Working Capital	-22.94	-0.2	-12.89	59.94

Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.